Acromegaly Before and After Surgery: Timeline, Hormone Changes, and Facial Recovery

Acromegaly surgery, usually transsphenoidal adenoma removal, produces measurable change within 24 hours: growth hormone (GH) falls sharply the night after resection, and roughly 60 to 85 percent of patients with microadenomas achieve biochemical remission (a fasting GH under 1.0 ng/mL and normalized IGF-1) within three months. Facial bone and skull changes do not reverse; soft-tissue swelling, ring and shoe size, sweating, and headaches often improve within weeks. The complete arc runs from a six-week pre-op workup through a 10-year surveillance window, and the pace of each change differs by tissue type.

The mechanism: why one small tumor reshapes the whole body

Acromegaly begins with a GH-secreting pituitary adenoma, a benign tumor that usually measures 4 to 15 mm. The tumor escapes normal feedback because pituitary GH release is normally pulsed and suppressed by IGF-1; a monoclonal adenoma ignores that brake and secretes GH continuously.

The damage is mostly indirect. GH itself has a half-life of only about 20 minutes in circulation, so it acts largely by triggering the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 has a half-life of roughly 12 to 15 hours and is the workhorse hormone that drives soft-tissue overgrowth, joint cartilage thickening, and organ enlargement. This two-step relay explains why IGF-1 is the better screening and monitoring marker: it integrates GH output over a full day instead of catching one random pulse.

Surgery works because it removes the source. Once the adenoma is gone, GH pulses normalize within hours and IGF-1 follows over one to two weeks because of its longer half-life. In plain terms: the tumor is the faucet, IGF-1 is the water already in the pipes, and the pipes drain slowly after the tap closes.

A non-obvious wrinkle: a subset of tumors co-secrete prolactin (about 25 to 40 percent in some series), and those patients often need dopamine-agonist therapy even after a clean resection. Surgeons also face invasion into the cavernous sinus in roughly 25 to 35 percent of macroadenomas, which caps how completely the tumor can be removed without damaging cranial nerves.

Before surgery: the six-week workup and what each test measures

The preoperative phase typically spans four to eight weeks and has one job: prove the diagnosis, map the tumor, and set a baseline so remission can be judged later. Skipping any step produces a "was it ever controlled?" ambiguity after surgery.

Diagnosis rests on two numbers. A random GH above 1.0 ng/mL plus an IGF-1 above the age-adjusted upper limit triggers confirmation, usually with an oral glucose tolerance test where GH fails to suppress below 1.0 ng/mL. An MRI with contrast then locates the adenoma and grades cavernous sinus invasion (Knosp grade 0 to 4); Knosp grade 3 or 4 predicts lower remission odds.

Preoperative medical therapy is a contested area. Somatostatin receptor ligands such as octreotide or lanreotide can shrink tumor volume by 20 to 50 percent in selected patients and may improve soft-tissue swelling before the operation. The trade-off: some evidence suggests pretreatment can blur the surgical planes, and the 2014 Endocrine Society clinical practice guideline does not mandate it for every patient. The decision usually hinges on tumor size, cardiac risk, and airway compromise.

A dedicated pre-op checklist lowers complication rates:

• Cardiac echocardiogram, because GH excess causes cardiomyopathy in 60 percent or more of long-standing cases.
• Sleep apnea screening, present in up to 70 percent of patients and a major anesthesia risk.
• HbA1c and fasting glucose, since diabetes affects 20 to 30 percent of patients.
• Colonoscopy if not current, because GH excess raises polyp and cancer risk.
• Blood pressure and joint assessment as functional baselines.
• Dental and airway evaluation, since macroglossia (enlarged tongue) complicates intubation.

Acromegaly before and after surgery: the comparison table

The table below reconciles the key before-and-after measures. It uses US customary labs where possible; GH and IGF-1 are reported in ng/mL because that is how clinical labs in the United States report them.

The critical distinction is between tissue that can shrink and bone that cannot. Soft tissue, cartilage, and organ size respond to falling IGF-1 within months; the mandible, skull, and enlarged hands' bony architecture are permanently remodeled. A patient whose face looks noticeably softer after a year has still not lost the widened jaw.

The post-surgery timeline: hour-by-hour to year-by-year

The time course after transsphenoidal resection is tightly scripted, and knowing it prevents both panic and false reassurance.

Two numbers need reconciling here. A single post-op GH under 2 ng/mL within 24 hours is a good sign but not proof of remission; the formal target is a fasting GH under 1.0 ng/mL plus a normal age-adjusted IGF-1, checked at four to six weeks. Some surgeons also use the oral glucose suppression test at three months for confirmation when results are borderline. These thresholds are complementary, not competing: the 24-hour GH reflects immediate tumor removal, while the one-month IGF-1 reflects sustained control.

The recurrence window matters. Most recurrences appear within the first five years, which is why surveillance is annual for a decade, then spaced longer if stable. Late recurrences beyond 10 years are reported but rare.

Recovery by body system: face, hands, heart, and joints

Different tissues recover at different speeds, and this is where patient expectations most often collide with reality.

Facial change is the most visible. Soft-tissue swelling around the cheeks, lips, and forehead often eases within three to six months; patients frequently report looking "less puffy." Bony changes such as frontal bossing, a protruding lower jaw, and widened tooth spacing persist and may need orthodontic or maxillofacial input. Skin thickening (cutis verticis gyrata on the scalp) improves slowly and unpredictably.

Hands and feet shrink modestly. Studies report average reductions of roughly half a shoe size and a partial ring size within a year, not a full return to pre-disease dimensions. Patients should not buy new shoes or rings in the first three months, because a premature purchase wastes money.

The heart is a major win. GH-driven cardiomyopathy can regress with control; left ventricular mass often falls measurably within 6 to 12 months of biochemical remission. Blood pressure improves in many patients but not all, because some hypertension becomes fixed after years of remodeling.

Joints are the least forgiving system. Arthropathy in the knees, hips, and spine is often irreversible; many patients report joint pain that persists or even worsens as soft-tissue support changes. This is a corrected misconception worth stating plainly: surgery controls the hormone, not every downstream damage.

Sleep apnea and sweating tend to improve early, sometimes within weeks, as upper airway soft tissue shrinks.

When surgery does not fully work: residual tumor and medical backup

Not every operation is curative, and the numbers are the reason the field keeps second-line therapies ready. Remission ranges from roughly 85 percent for microadenomas to 50 to 70 percent for macroadenomas, with cavernous sinus invasion and large tumor size as the main predictors of failure.

A residual tumor detected on a three-month MRI is not automatically a failure. Some patients achieve normal IGF-1 despite a small remnant, and the decision between reoperation, radiation, or medication depends on hormone levels, invasion, and patient preference. A second transsphenoidal procedure is an option in selected cases, but repeat surgery carries higher risk of hypopituitarism (new pituitary hormone deficiency) in roughly 10 to 20 percent of reoperations.

Medical therapy fills the gap. Somatostatin receptor ligands (octreotide, lanreotide, and the long-acting pasireotide) control IGF-1 in a substantial share of patients; pegvisomant, a GH receptor blocker, normalizes IGF-1 in most patients but requires monitoring of liver enzymes. Cabergoline helps the prolactin-co-secreting subgroup. Radiation, usually stereotactic, is reserved for residual disease and works slowly over years, with hypopituitarism risk rising over time.

One professional caveat: a normal IGF-1 does not guarantee a cured tumor if a remnant is visible, and a visible remnant does not guarantee failure if hormones are controlled. The two must be read together.

What to actually do: a patient-and-clinician action list

Concrete steps work better than vague advice, and the sequence below reflects standard endocrine and neurosurgical practice.

• Confirm both GH and IGF-1 before any treatment, and keep a copy of the baseline values, because post-op comparisons depend on them.
• Get a contrast MRI with cavernous sinus grading (Knosp) before surgery so expectations about remission odds are realistic.
• Complete the cardiac, sleep apnea, and glucose workup in the four to eight weeks before the operation.
• Draw the first post-op GH within 24 hours, then the formal IGF-1 at four to six weeks, not sooner.
• Avoid buying new shoes or rings until at least three months post-op.
• Commit to annual hormone and MRI surveillance for 10 years, because recurrence peaks in the first five.

Expectations should be set on both sides of the table. Patients should know that soft tissue improves but bone does not; clinicians should warn that joint pain may persist even with perfect biochemical control.

Limits of the evidence and what remains uncertain

The honest summary is that long-term outcome data for acromegaly surgery are strong but not uniform. Most published remission rates come from single-center series with different remission criteria, different surgical techniques (microscopic versus endoscopic), and follow-up periods that vary from two to 15 years. Pooling them produces a range, not a single truth.

Several questions remain open. The benefit of preoperative somatostatin ligand therapy on final remission is still debated, with conflicting trial evidence. The optimal surveillance interval beyond five years is not standardized, and some guidelines suggest extending it beyond 10 years, while others do not. Whether early surgery in patients with mild, biochemically borderline disease improves outcomes compared with watchful medical management is an active area of research.

What is not uncertain: surgery remains first-line for most patients, remission is the goal rather than a guarantee, and the tissue-specific recovery pattern (soft tissue reversible, bone permanent) is consistent across studies. Anyone weighing acromegaly before and after surgery should plan for the long surveillance tail, not just the operation itself.

Per the 2014 Endocrine Society clinical practice guideline, the diagnosis and remission criteria used throughout this article (fasting GH under 1.0 ng/mL and age-adjusted IGF-1) are the accepted standards, though individual centers may apply slightly different cutoffs and should state them explicitly.